Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.53 |
| ▸ | CA2 | P00918 | 8/20 | 0.53 |
| ▸ | CA12 | O43570 | 4/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CCND3 | P30281 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31135860 | 1.00 | CA1 (0.53) | CA1CA2CA12CA7CA14 | |
| SCHEMBL28304436 | 0.96 | CA1 (0.49) | CA1CA2CA12CA7CA14 | |
| SCHEMBL29650253 | 0.79 | ADRA2A (0.41) | CA1CA2CA12CA7CA14 | |
| SCHEMBL19693184 | 0.79 | ADRA2A (0.41) | CA1CA2CA12CA7CA14 | |
| Hydrochloric Acid SCHEMBL28291820 | 0.77 | ADRA2A (0.47) | CA1CA2CA12CA7CA14 | |
| SCHEMBL21327723 | 0.73 | CHRNA7 (0.54) | — | |
| SCHEMBL5464319 | 0.71 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CLMNACYP11B2 | |
| SCHEMBL29791251 | 0.71 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CLMNACYP11B2 | |
| SCHEMBL29519756 | 0.69 | CA1 (1.00) | CA1CA2CA12CA7CA14 | |
| SCHEMBL2011443 | 0.69 | CA1 (1.00) | CA1CA2CA12CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | UNIV QUEENSLAND (AU) | 2024-12-05 | — | — | US | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-20220112159-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | UNIV QUEENSLAND (AU) | 2022-04-14 | — | — | US | disclosed |
| EP-3888749-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | The University of Queensland (AU) | 2021-10-06 | — | — | EP | disclosed |
| US-11130731-B2 | Sulfonylureas and related compounds and use of same | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2021-09-28 | — | — | US | disclosed |
| EP-3578547-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | The University of Queensland (AU) | 2019-12-11 | — | — | EP | disclosed |
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | INFLAZOME LIMITED (IE) | 2018-02-15 | — | — | US | disclosed |
| EP-3259253-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | The University of Queensland (AU) | 2017-12-27 | — | — | EP | disclosed |
| WO-2016131098-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112159-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | CA1 4141/4885CA2 2434/4885CA12 4653/4885 |
| US-11845715-B2 | — | NLRP3, PYCARD, NOD1 | CA1 4541/4885CA2 3818/4885CA12 4772/4885 |
| US-11130731-B2 | Sulfonylureas and related compounds and use of same | NLRP3, PYCARD, IAPP | CA1 4141/4885CA2 2434/4885CA12 4653/4885 |
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | CA1 4141/4885CA2 2434/4885CA12 4653/4885 |
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | CA1 4141/4885CA2 2434/4885CA12 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.